Financial Performance - The company's operating revenue for the third quarter was ¥114,539,032.74, a decrease of 6.54% compared to the same period last year[4]. - The total profit for the year-to-date period reached ¥25,365,780.91, with a net profit attributable to shareholders of ¥27,632,247.92[4]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -¥17,364,632.37 for the third quarter[4]. - Total operating revenue for the first three quarters of 2025 was CNY 350,629,873.70, a decrease of 2.14% compared to CNY 359,402,017.18 in the same period of 2024[20]. - Net profit for the first three quarters of 2025 was CNY 27,627,752.51, a turnaround from a net loss of CNY 28,400,706.00 in the same period of 2024[22]. - The company reported a total profit of CNY 25,365,780.91 for the first three quarters of 2025, compared to a total loss of CNY 22,988,834.03 in the previous year[22]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥60,020,426.83, representing a significant increase of 417.50%[5]. - Cash inflow from operating activities for the first three quarters of 2025 reached approximately $422.92 million, an increase from $406.77 million in the same period of 2024, representing a growth of about 4%[24]. - The net cash flow from operating activities significantly improved to $60.02 million in 2025, compared to $11.60 million in 2024, indicating a substantial increase in operational efficiency[24]. - Total cash outflow for operating activities was approximately $362.90 million in 2025, a decrease from $395.17 million in 2024, indicating better cost management[24]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,131,853,844.83, reflecting a 1.22% increase from the end of the previous year[5]. - Total current assets increased to ¥418,032,263.40 from ¥366,665,116.02, a growth of approximately 14.0%[15]. - Total liabilities decreased slightly to CNY 513,251,593.45 from CNY 516,587,993.08[20]. - Non-current assets totaled ¥1,713,821,581.43, down from ¥1,739,587,919.89, a decrease of approximately 1.5%[16]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 28,285[12]. - Shanghai Yanghe Industrial Co., Ltd. holds 20.82% of shares, with 78,249,836 shares pledged[12]. - Chen Dekang, a natural person, holds 11.67% of shares, totaling 43,871,004 shares[12]. Earnings Per Share - The basic earnings per share for the third quarter was ¥0.01, unchanged from the previous year[5]. - The diluted earnings per share for the third quarter was also ¥0.01, consistent with the previous year[5]. - Basic earnings per share for the first three quarters of 2025 was CNY 0.07, compared to a loss of CNY 0.08 in the same period of 2024[22]. Cost Management - The company has implemented cost control measures, resulting in a reduction in management expenses compared to the previous year[9]. - Total operating costs decreased significantly to CNY 336,856,292.82 from CNY 401,137,647.70, representing a reduction of approximately 16.06%[21]. - Research and development expenses decreased to CNY 14,861,974.29 from CNY 44,765,811.58, a reduction of approximately 66.8%[21]. Government Subsidies - The company reported a significant increase in government subsidies recognized, amounting to ¥1,583,793.41 for the year-to-date period[7]. Investment Activities - Cash outflow from investment activities totaled approximately $127.50 million in 2025, a decrease from $282.94 million in 2024, reflecting a reduction in capital expenditures[25]. - The net cash flow from investment activities was negative at -$85.68 million in 2025, an improvement from -$188.69 million in 2024, suggesting better investment management[25]. - The company received approximately $40.47 million from other investment-related cash inflows in 2025, a significant increase from $10.09 million in 2024, reflecting improved investment returns[25]. Financial Reporting - The company did not apply new accounting standards for the first time in 2025, maintaining consistency in financial reporting[26].

浙江莎普爱思药业股份有限公司 ZhejiangShapuaisiPharmaceuticalCo.，Ltd. (603168) 章程 (2025 年 10 月修订) | | | 第一章 总则 公司通过有限公司整体变更以发起方式设立；公司在浙江省市场 监督管理局注册登记，取得营业执照。统一社会信用代码： 91330000146644116H。 2 第一条 为维护浙江莎普爱思药业股份有限公司(以下简称"公司")、股东、 职工和债权人的合法权益，规范公司的组织和行为，根据《中国 共产党党章》（以下简称"《党章》"）、《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）、《上海证券交易所股票上市规则》以及其他有关规 定，制定本章程。 第二条 公司系依照《公司法》、《证券法》和其他有关规定成立的股份有 限公司。 第三条 公司于 2014 年 6 月 9 日经中国证券监督管理委员会(以下简称"中 国证监会")批准，首次向社会公众发行人民币普通股 1，635 万股， 于 2014 年 7 月 2 日在上海证券交易所(以下简称"证券交易所") 上市。 第四条 公司注册名称 ...

Core Viewpoint - The company reported a decline in revenue and net profit for the third quarter of 2025 compared to the previous year, indicating potential challenges in its financial performance [1] Financial Performance - In the third quarter of 2025, the company achieved an operating income of 115 million yuan, a year-on-year decrease of 6.54% [1] - The net profit attributable to shareholders was 5.7694 million yuan, with a basic earnings per share of 0.01 yuan [1] - For the first three quarters of 2025, the company reported an operating income of 351 million yuan, down 2.44% year-on-year [1] - The net profit attributable to shareholders for the first three quarters was 27.6322 million yuan, with a basic earnings per share of 0.07 yuan [1]

Core Viewpoint - On October 27, a total of 10 listed companies had their restricted shares unlocked, with a total market value of approximately 18.54 billion yuan [1] Summary by Category Restricted Share Unlocking - Xiamen Bank (601187) extended the lock-up period for 1.348 billion shares [1] - Guangzheng Eye Hospital (002524) released 2.2245 million shares under equity incentive restrictions [1] - Shapuaisi (603168) released 30,000 shares under equity incentive restrictions [1] - Yifeng Pharmacy (603939) released 195,000 shares under equity incentive restrictions [1] - Jihong Co., Ltd. (002803) released 1.98 million shares under equity incentive restrictions [1] - Mingyang Circuit (300739) released 1.2387 million shares under equity incentive restrictions [1] - Arrow Home (001322) released 800 million shares under pre-issue restrictions [1] - Ruichen Environmental Protection (301273) released 3.70125 million shares under pre-issue restrictions [1] - Jinchengzi (688291) released 6.9 million shares [1] - Weice Technology (688372) released 2.70328 million shares [1]

证券日报网讯 10月24日晚间，莎普爱思发布公告称，近日，公司组织开展的立他司特滴眼液Ⅲ期临床 试验完成首例受试者入组。 （文章来源：证券日报） ...

财经频道更多独家策划、专家专栏，免费查阅>>责任编辑：钟离 格隆汇10月24日丨莎普爱思(603168.SH)公布，公司收到国家药品监督管理局核发的盐酸奥布卡因滴眼 液的《药品注册证书》（证书编号：2025S03202），本次获批的盐酸奥布卡因滴眼液，可用于眼科领 域内的表面麻醉。 ...

Core Viewpoint - The company has completed the enrollment of the first subject in the Phase III clinical trial for Latanoprost eye drops, aimed at evaluating its efficacy and safety in treating dry eye in the Chinese population [1] Group 1 - The Phase III clinical trial is designed as a multi-center, randomized, double-blind, placebo-controlled study [1] - The trial's primary focus is to assess the effectiveness and safety of Latanoprost eye drops in the treatment of dry eye [1] - The first subject was enrolled on October 23, 2025 [1]

格隆汇10月24日丨莎普爱思(603168.SH)公布，公司收到国家药品监督管理局核发的盐酸奥布卡因滴眼 液的《药品注册证书》（证书编号：2025S03202），本次获批的盐酸奥布卡因滴眼液，可用于眼科领 域内的表面麻醉。 ...

药品批准文号：国药准字H20255752 证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-059 浙江莎普爱思药业股份有限公司 关于获得盐酸奥布卡因滴眼液 《药品注册证书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江莎普爱思药业股份有限公司（以下简称"公司"、"莎普爱思"）收到 国家药品监督管理局核发的盐酸奥布卡因滴眼液的《药品注册证书》（证书编号： 2025S03202），现将有关信息公告如下： 一、《药品注册证书》主要内容 药品名称：盐酸奥布卡因滴眼液 剂型：眼用制剂 规格：0.4%（0.5ml：2mg） 注册分类：化学药品4类 上市许可持有人：浙江莎普爱思药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药 品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他情况 本次获批的盐酸奥布卡因滴眼液，可用于眼科领域内的表面麻醉。 截至本公告披露日，公司针对该药品的累计研发投入约为 372.64 万元人民币。 三、对公司的影响、后续安排及风险 ...

证券代码：603168 证券简称：莎普爱思 公告编号：临 2025-060 剂型：眼用制剂 注册分类：化学药品3类 二、立他司特滴眼液临床试验相关情况 立他司特滴眼液Ⅲ期临床试验，采用多中心、随机、双盲、安慰剂平行对照 设计，评价立他司特滴眼液在中国人群中治疗干眼的有效性和安全性，已于2025 年10月23日完成首例受试者入组。 截至本公告披露日，立他司特滴眼液项目累计研发投入约1,915.15万元人民 币。 浙江莎普爱思药业股份有限公司 关于立他司特滴眼液 III 期临床试验 完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江莎普爱思药业股份有限公司（以下简称"公司"）组织开展的立 他司特滴眼液III期临床试验完成首例受试者入组。具体情况如下： 一、立他司特滴眼液基本情况 药品名称：立他司特滴眼液 三、风险提示 根据中国药品注册相关的法律法规要求，药物在获得临床试验批准后，须完 成临床试验方可进行药品注册上市许可申请。 由于药物研发的特殊性，药物从临床试验到投产的周期长，环节多，易受不 可预 ...